Publications by authors named "A Quintas Viqueira"
Article Synopsis
- * At the end of the study, nearly half of the patients were still on treatment, with significant percentages achieving major molecular response (71.8%) and molecular response (59.7%), indicating the drug’s ability to improve disease control.
- * The 48-month survival rate was high (88.3%), and while some adverse events were noted, they were in line with known side effects of bosutinib, highlighting its long-term efficacy and
The BYOND study evaluated the efficacy and safety of bosutinib 500 mg once daily in patients with chronic myeloid leukemia (CML) resistant/intolerant to prior tyrosine kinase inhibitors (TKIs). These post-hoc analyses assessed the efficacy and safety of bosutinib by resistance or intolerance to prior TKIs (imatinib-resistant vs dasatinib/nilotinib-resistant vs TKI-intolerant), and cross-intolerance between bosutinib and prior TKIs (imatinib, dasatinib, nilotinib), in patients with Philadelphia chromosome-positive chronic phase CML. Data are reported after ≥3 years' follow-up.
View Article and Find Full Text PDFElranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing.
View Article and Find Full Text PDF